6 European Projects Found
Searched on 125080 European Projects
FINISHED
Does vascular endothelial growth factor gene therapy safely improve outcome in severe early-onset fetal growth restriction? (EVERREST)
Start date: Jan 1, 2013, End date: Dec 31, 2018,
Fetal growth restriction (FGR) globally occurs in 8% of pregnancies, is severe and early onset in 1:500 cases, affecting 11,000 babies annually in the EU. In most cases, reduced uterine blood flow restricts substrate delivery to the fetus causing growth to slow or cease. There is no treatment. Currently the fetus is delivered very preterm before fetal death or irreversible organ damage occurs. Aff ...
Read Project
10
Partners Participants
FINISHED
Tissue engineering of the right heart outflow tract by a biofunctionalized bioresorbable polymeric valved tube (TEH-TUBE)
Start date: Jan 1, 2014, End date: Dec 31, 2017,
Approximately 42% of infants’ mortality in the world is related to congenital heart defects (prevalence: 8-12/1000 births). Over 1/3 require the reconstruction of the right ventricular outflow tract (RVOT) by surgical procedures which currently use inert materials without any growth potential. Consequently, multiple reoperations are often required, with their attendant high risk of mortality and m ...
Read Project
7
Partners Participants
FINISHED
The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BM-MNC) on all-cause mortality in acute myocardial infarction (BAMI)
Start date: Nov 1, 2011, End date: Oct 31, 2017,
Although the long term prognosis of patients suffering acute myocardial infarction (AMI) has improved since the introduction of reperfusion therapies and primary angioplasty, the 1 year mortality of patients with AMI and resultant left ventricular systolic dysfunction (LVSD) is still as high as 13%. A major reason for the high morbidity and mortality is that the heart has an inadequate regenerativ ...
Read Project
23
Partners Participants
FINISHED
Biodegradable Magnetic Stent for Coronary Artery Luminal Regeneration (BIOMAGSCAR)
Start date: Jan 1, 2012, End date: Dec 31, 2016,
By 2010 1.5 million stents per year will be deployed in Europe. Although outcome for patients has improved, stents still fail because of the occurrence of restenosis and thrombosis at the site of implantation. While drug eluting stents have helped to reduce the problem of restenosis, neointimal proliferation causing restenosis can still occur. Additional concerns exist regarding drug eluting stent ...
Read Project
8
Partners Participants
FINISHED
EPIGENETICS FOR FEMALE PERSONALIZED CANCER CARE (EPI-FEM-CARE)
Start date: Nov 1, 2012, End date: Apr 30, 2016,
CLINICAL NEEDEvery year in the EU ~45,300 and 330,000 women are diagnosed with ovarian and breast cancer respectively & 28,800 and 90,000 of these two groups of women will die as a consequence of these diseases. Currently there are no tools available that allow for:a) Effective screening of ovarian and/or breast cancer of sufficient sensitivity and specificity to avoid potential over-diagnosis, or ...
Read Project
6
Partners Participants
FINISHED
Development of OPN-305 as an orphan drug for the treatment of Delayed Graft Function post solid organ transplantation (MABSOT)
Start date: Dec 1, 2010, End date: Sep 30, 2014,
Delayed graft function (DGF) is defined as the need for dialysis within seven days of renal transplantation (DGF promotes allograft rejection, requires prolonged dialysis and hospitalisation, and increases the likelihood of graft failure and ultimately the duration of renal graft survival-expectancy. The incidence of DGF occurs in 21-44% of cases following cadaveric renal graft. Several rare dise ...
Read Project
